PURPOSE: We explored the imaging of bombesin receptors and evaluated the clinical use of [(99m)Tc]Demobesin 4 ([(99m)Tc]DB4) in prostate cancer patients. PROCEDURES: [(99m)Tc]DB4 was prepared according to Good Manufacturing Practice. Patients with prostate cancer underwent serial planar and SPECT imaging up to 3 h after administration. Blood and urine samples were taken to assess pharmacokinetics. RESULTS: [(99m)Tc]DB4 is safe and clears rapidly from the bloodstream via the kidneys resulting in low background activity. The tracer binds strongly to the gastrin-releasing peptide receptor (GRPR) in vivo as indicated by the high uptake in the pancreas seen in all patients. In patients who had undergone hormone therapy, [(99m)Tc]DB4 did not efficiently image metastatic prostate cancer. In contrast, in newly diagnosed patients local disease was visualised. CONCLUSIONS: The GRPR is an unsuitable target for imaging refractory prostate cancer but may be useful in untreated disease. [(99m)Tc]DB4 is a promising radiopharmaceutical which merits further exploration in this specific group of patients.
PURPOSE: We explored the imaging of bombesin receptors and evaluated the clinical use of [(99m)Tc]Demobesin 4 ([(99m)Tc]DB4) in prostate cancer patients. PROCEDURES: [(99m)Tc]DB4 was prepared according to Good Manufacturing Practice. Patients with prostate cancer underwent serial planar and SPECT imaging up to 3 h after administration. Blood and urine samples were taken to assess pharmacokinetics. RESULTS: [(99m)Tc]DB4 is safe and clears rapidly from the bloodstream via the kidneys resulting in low background activity. The tracer binds strongly to the gastrin-releasing peptide receptor (GRPR) in vivo as indicated by the high uptake in the pancreas seen in all patients. In patients who had undergone hormone therapy, [(99m)Tc]DB4 did not efficiently image metastatic prostate cancer. In contrast, in newly diagnosed patients local disease was visualised. CONCLUSIONS: The GRPR is an unsuitable target for imaging refractory prostate cancer but may be useful in untreated disease. [(99m)Tc]DB4 is a promising radiopharmaceutical which merits further exploration in this specific group of patients.
Authors: Francesco Scopinaro; Giuseppe De Vincentis; Alexandra D Varvarigou; Cesare Laurenti; Francesco Iori; Silvia Remediani; Stella Chiarini; Salvatore Stella Journal: Eur J Nucl Med Mol Imaging Date: 2003-08-21 Impact factor: 9.236
Authors: Antonia Dimitrakopoulou-Strauss; Peter Hohenberger; Uwe Haberkorn; Helmut R Mäcke; Michael Eisenhut; Ludwig G Strauss Journal: J Nucl Med Date: 2007-07-13 Impact factor: 10.057
Authors: Clemens Decristoforo; Theodosia Maina; Berthold Nock; Michael Gabriel; Paul Cordopatis; Roy Moncayo Journal: Eur J Nucl Med Mol Imaging Date: 2003-07-04 Impact factor: 9.236
Authors: Francesco Scopinaro; Giuseppe De Vincentis; Enrico Corazziari; Rita Massa; Mattia Osti; Nadia Pallotta; Alfredo Covotta; Silvia Remediani; Maria Di Paolo; Francesco Monteleone; Alexandra Varvarigou Journal: Cancer Biother Radiopharm Date: 2004-04 Impact factor: 3.099
Authors: Hildo J K Ananias; Zilin Yu; Hilde D Hoving; Stefano Rosati; Rudi A Dierckx; Fan Wang; Yongjun Yan; Xiaoyuan Chen; Jan Pruim; Marjolijn N Lub-de Hooge; Wijnand Helfrich; Philip H Elsinga; Igle J de Jong Journal: Nucl Med Biol Date: 2013-07-26 Impact factor: 2.408
Authors: Esa Kähkönen; Ivan Jambor; Jukka Kemppainen; Kaisa Lehtiö; Tove J Grönroos; Anna Kuisma; Pauliina Luoto; Henri J Sipilä; Tuula Tolvanen; Kalle Alanen; Jonna Silén; Markku Kallajoki; Anne Roivainen; Niklaus Schäfer; Roger Schibli; Martina Dragic; Anass Johayem; Ray Valencia; Sandra Borkowski; Heikki Minn Journal: Clin Cancer Res Date: 2013-08-09 Impact factor: 12.531
Authors: Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen Journal: Peptides Date: 2015-05-11 Impact factor: 3.750
Authors: Kwanghee Kim; Hanwen Zhang; Stephen La Rosa; Sylvia Jebiwott; Pooja Desai; Simon Kimm; Avigdor Scherz; Joseph A O'Donoghue; Wolfgang A Weber; Jonathan A Coleman Journal: Clin Cancer Res Date: 2017-01-20 Impact factor: 12.531
Authors: Gesche Wieser; Ilinca Popp; H Christian Rischke; Vanessa Drendel; Anca-Ligia Grosu; Mark Bartholomä; Wolfgang A Weber; Rosalba Mansi; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Philipp T Meyer; Cordula Annette Jilg Journal: Eur J Nucl Med Mol Imaging Date: 2017-04-18 Impact factor: 9.236
Authors: Theodosia Maina; Hendrik Bergsma; Harshad R Kulkarni; Dirk Mueller; David Charalambidis; Eric P Krenning; Berthold A Nock; Marion de Jong; Richard P Baum Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-02 Impact factor: 9.236
Authors: Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova Journal: Pharmaceutics Date: 2021-01-30 Impact factor: 6.321
Authors: Panagiotis Kanellopoulos; Aikaterini Kaloudi; Maritina Rouchota; George Loudos; Marion de Jong; Eric P Krenning; Berthold A Nock; Theodosia Maina Journal: Pharmaceutics Date: 2020-11-26 Impact factor: 6.321